Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For participants with HIV taking either lopinavir or fosamprenavir who have elevated triglycerides, this trial will study the change in triglycerides after switching protease inhibitors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

NCT00757783

HIV

COMPLETED PHASE4

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

NCT00120393

HIV Infections

COMPLETED PHASE3

Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)

NCT00028301

HIV Infections

COMPLETED PHASE3

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009

Human Immunodeficiency Virus Infection

COMPLETED PHASE3

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

NCT01073761

HIV HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This Phase IV trial will look at lipid and virologic responses after a switch to a more lipid-friendly antiretroviral regimen. Participants will be randomized to receive either boosted atazanavir or boosted darunavir given once daily, along with background NRTIs. This 24-week study will require 4 visits after randomization for evaluation, monitoring, and lab studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Switch to DRV/r (800mg/100mg) QD

We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Group Type OTHER

DRV/r

Intervention Type DRUG

We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Switch to ATV/r (300mg/100mg QD)

We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study

Group Type OTHER

ATV/r

Intervention Type DRUG

Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATV/r

Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Intervention Type DRUG

DRV/r

We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Atazanavir/r

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Currently receiving Antiretroviral Therapy (ART) regimen including LPV/r or FPV/r and \> or equal to 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Patient must be on a stable regimen containing LPV/r or FPV/r for at least 12 weeks prior to screening.
* Documentation of an undetectable Human Immunodeficiency Virus (HIV) viral load (VL\<400 copies/ml) using an FDA approved assay for a minimum of twelve weeks prior to screening AND undetectable HIV viral load using an FDA approved ultrasensitive assay at screening.
* No evidence of HIV protease resistance as defined by the Stanford HIV database
* Currently receiving first protease inhibitor unless switch to LPV/r or FPV/r was for non-virologic reasons
* Fasting triglycerides \> 200 mg/dL
* No ongoing issues that in the opinion of the investigator would lead to decreased ability to comply with the study procedures
* If currently receiving a proton pump inhibitor, the dose is \< omeprazole 20 mg or the equivalent dose of another proton pump inhibitor
* If patient is receiving another lipid lowering medication, it must be at a stable dose

Exclusion Criteria

* Currently receiving an ART regimen other than \> or equal to two NRTIs and either LPV/r or FPV/r
* Prior use of darunavir or atazanavir
* CDC Class C Illness diagnosed within 30 days of screening
* Patient is currently receiving the following Hydroxamethylglutaryl-coA (HMGCoA) reductase inhibitor medications (statins): pravastatin, lovastatin, simvastatin
* Patient is currently receiving a bile acid sequestrant (cholestyramine, colestipol, and colesevelam)
* Grade 3 or 4 Laboratory abnormalities as defined by a standardized grading scheme based on the DAIDS table with the following exceptions:

1. Pre-existing diabetes mellitus with asymptomatic, nonfasting glucose grade 3 elevations
2. Subjects with asymptomatic grade 3 fasting triglyceride or cholesterol elevations
* Clinical or laboratory evidence of clinically significant liver impairment/dysfunction disease or cirrhosis
* Note: Individuals co-infected with chronic hepatitis B or C viruses will be allowed to enter the trial if their condition is clinically stable and they will not require therapy during the course of the study. Individuals diagnosed with acute viral hepatitis at screening will not be allowed to enroll during acute phase
* Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance
* Use of any investigational agents 30 days prior to screening
* Life expectancy \< 6 months in the opinion of the investigator
* Pregnancy or breast feeding
* Female subject of childbearing potential (i.e., heterosexually active, and not surgically sterile or at least two years post-menopausal) not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No